The Effects of a Web-based Tool for Parents of Children with Juvenile Idiopathic Arthritis: Randomised Controlled Trial by Mulligan, K. et al.
              
City, University of London Institutional Repository
Citation: Mulligan, K. ORCID: 0000-0002-6003-3029, Hirani, S. P. ORCID: 0000-0002-
1577-8806, Harris, S., Taylor, J., Wedderburn, L. R. and Newman, S. (2021). The Effects of 
a Web-based Tool for Parents of Children with Juvenile Idiopathic Arthritis: Randomised 
Controlled Trial. Journal of Medical Internet Research, 
This is the accepted version of the paper. 
This version of the publication may differ from the final published version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/27319/
Link to published version: 
Copyright: City Research Online aims to make research outputs of City, 
University of London available to a wider audience. Copyright and Moral Rights 
remain with the author(s) and/or copyright holders. URLs from City Research 
Online may be freely distributed and linked to.
Reuse: Copies of full items can be used for personal research or study, 
educational, or not-for-profit purposes without prior permission or charge. 
Provided that the authors, title and full bibliographic details are credited, a 
hyperlink and/or URL is given for the original metadata page and the content is 
not changed in any way. 
City Research Online
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
1 
 
Title Page  1 
Title: The Effects of a Web-based Tool for Parents of Children with Juvenile Idiopathic Arthritis: 2 
Randomised Controlled Trial. 3 
 4 
Kathleen Mulligan BSc MSc PhD1,2, Shashivadan P Hirani BSc MSc PhD1, Sally Harris3, BSc MSc PhD 5 
ClinPsyD, Jo Taylor1 BSc MSc, Lucy R Wedderburn BA MBBS PhD FRCP4,5,6, Stanton P Newman DPhil 6 
Dip Psych FBPS1, 7 on behalf of the WebParC Investigator Groupⴕ.  7 
1.City, University of London, London, UK 2. East London NHS Foundation Trust, London, UK 3. 8 
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK 4. UCL GOS Institute of Child 9 
Health, University College London, London, UK 5. Centre for Adolescent Rheumatology Versus 10 
Arthritis, London, UK 6. NIHR Biomedical Research Centre at GOSH, London, UK 7. Division of 11 
Medicine, UCL.  12 
Corresponding author: Professor Stanton Newman stanton.newman.1@city.ac.uk 13 
Centre for Health Services Research, School of Health Sciences, City, University of London, 14 
Northampton Square, London EC1V 0HB. Tel: 020 7040 3090 15 
 16 
ⴕ WebParC Investigator Group: 17 
Dr Eslam Al-Abadi, Birmingham Children's Hospital; Dr Muthana Al-Obaidi, Department of Paediatric 18 
Rheumatology, Great Ormond Street Hospital NHS Foundation Trust,  19 
Infection, Inflammation and Rheumatology Section; NIHR Biomedical Research Centre, UCL Great 20 
Ormond Street Institute of Child Health; Dr Kate Armon, Addenbrooke’s Hospital, Cambridge and 21 
Norfolk & Norwich University Hospital; Dr Kathy Bailey, Oxford University Hospitals; Lyndsey Bibb, 22 
New Cross Hospital, Wolverhampton; Dr Richard Brough, Shrewsbury & Telford Hospital NHS Trust; 23 
Katrin Buerkle, City, University of London; Jo Bytham, Addenbrooke’s Hospital, Cambridge; Asyah 24 
Chhibda, Leeds Teaching Hospitals NHS Trust; Dr Alice Chieng, Royal Manchester Children's Hospital; 25 
Heather Chisem, Sheffield Children's NHS Foundation Trust; Louise Coke, Norfolk & Norwich 26 
2 
 
University Hospital; Dr Karen Davies, The Robert Jones and Agnes Hunt Orthopaedic Hospital; Dr 1 
Hans de Graaf, Southampton Children's Hospital; Rebecca Denyer, New Cross Hospital, 2 
Wolverhampton; Kirsty Devine, Great North Children's Hospital, Newcastle; Annette Duggan, Royal 3 
Manchester Children's Hospital; Andrea Edwards, Addenbrooke’s Hospital, Cambridge; Louisa Fear, 4 
Norfolk & Norwich University Hospital; Ruth Finch, Oxford University Hospitals; Dr Chris Flood, 5 
London South Bank University; Elizabeth Fofana, Southampton Children’s Hospital; Sara Foster, 6 
Addenbrooke’s Hospital, Cambridge; Sarah Hanson, Leeds Teaching Hospitals NHS Trust; Dr Sally 7 
Harris, Brighton and Sussex University Hospitals NHS Trust; Dr Kathryn Harrison, Birmingham 8 
Children's Hospital and University Hospital Coventry & Warwickshire; Dr Daniel P Hawley, Sheffield 9 
Children's NHS Foundation Trust; Eleanor Heaf, Royal Manchester Children's Hospital; Dr 10 
Shashivadan Hirani, City, University of London, Ruth Howman, Birmingham Children’s Hospital; 11 
James Jones, Shrewsbury and Telford Hospital NHS Trust; Ruth Jones, Royal Stoke University 12 
Hospital; Dr Alice Leahy, Southampton Children's Hospital; Dr Valentina Leone, Leeds Teaching 13 
Hospitals NHS Trust; Gail Lindsay, Addenbrooke’s Hospital, Cambridge; Carol Lydon, Alder Hey 14 
Children’s Hospital; Ian MacDonald, Great Ormond Street Hospital; Emma MacLeod,  Southampton 15 
Children’s Hospital; Dr Liza J McCann, Alder Hey Children's Hospital, Liverpool; Dr Flora McErlane, 16 
Great North Children's Hospital, Newcastle; Ann McGovern, Royal Manchester Children's Hospital; 17 
Diane Miller, Oxford University Hospitals; Dr Kathleen Mulligan, City, University of London; Maxine 18 
Mutten, Sheffield Children's NHS Foundation Trust; Professor Stanton P Newman, City, University of 19 
London; Tracy Oliver, Norfolk & Norwich University Hospital; Dr Jonathan Packham, Royal Stoke 20 
University Hospital; Helen Parker, Royal Stoke University Hospital; Sarrah Peerbux, City, University of 21 
London; Dr Clive Ryder, University Hospital Coventry & Warwickshire; Hilary Shepley, The Robert 22 
Jones and Agnes Hunt Orthopaedic Hospital; Dr Brian Shields, University Hospital Coventry & 23 
Warwickshire; Dr Taunton Southwood, Birmingham Children’s Hospital; Rebecca Steele, University 24 
Hospital Coventry & Warwickshire; Dr Alexandra Tabor, Royal Stoke University Hospital; Jo Taylor, 25 
City, University of London; Lowri Thomas, Sheffield Children's NHS Foundation Trust; Fiona 26 
3 
 
Thompson, University Hospital Coventry & Warwickshire; Louise Turner,  Leeds Teaching Hospitals 1 
NHS Trust; Sarah Turner, The Robert Jones and Agnes Hunt Orthopaedic Hospital; Susan Wadeson, 2 
Alder Hey Children’s Hospital; Diane Walia, Great North Children's Hospital, Newcastle; Joanna 3 
Watts, Norfolk & Norwich University Hospital; Nicola Watts, University Hospital Coventry & 4 
Warwickshire; Professor Lucy R Wedderburn, Great Ormond Street Hospital, Pauline Whitelaw, City, 5 
University of London. 6 
  7 
4 
 
Abstract  1 
Background: Juvenile idiopathic arthritis (JIA) is a group of autoinflammatory diseases, which cause 2 
pain and disability if not controlled by treatment.  Parenting a child with JIA is stressful for parents, 3 
who express concerns about their child’s treatment and may experience anxiety and powerlessness 4 
concerning their child’s illness. Parenting stress is greater in the parents of children with chronic 5 
illness than those of healthy children and is related to poorer psychological adjustment in both 6 
parents and children. It is therefore important to develop interventions to support parents. This 7 
paper reports the evaluation of a web-based tool that provides information and practical skills to 8 
help increase parents’ confidence in managing their child’s illness and reduce parenting stress. 9 
Objective: To evaluate the benefits of a web-based tool (“WebParC”) for parents of children with 10 
recently diagnosed JIA. 11 
Methods: A multi-centred randomised controlled trial was conducted in paediatric rheumatology 12 
centres in England. Parents of children aged ≤12 years, who had been diagnosed within JIA within 13 
the previous six months, were recruited when they attended clinic with their child. They were 14 
randomised to the Intervention (WebParC access plus standard care) or the Control (standard care 15 
alone), and followed up 4-months and 12-months post-randomisation. Where both parents 16 
participated, they were randomised ‘by household’ to the same trial arm. The WebParC intervention 17 
consists of information about JIA and its treatment plus a toolkit, based on cognitive-behavioural 18 
therapy, to help parents develop skills to manage JIA-related issues. 19 
The primary outcome was the self-report Pediatric Inventory for Parents (PIP) measure of illness-20 
related parenting stress. Secondary outcomes were: parental mood, self-efficacy, coping, 21 
effectiveness of participation in their child’s healthcare, satisfaction with healthcare and child 22 
health-related quality of life (HRQoL). 23 
5 
 
Results: A total of 203 ‘households’, comprising 220 parents, were randomised to the Intervention 1 
(n=100) or Control (n=103) arm. Follow-up assessments were completed by 133 households (65.5%) 2 
at 4-months (60 households Intervention, 73 Control) and 124 (61.1%) (58 households Intervention, 3 
66 Controls) at 12-months.  4 
A main effect of trial-arm was found on the PIP; Intervention participants reported less frequency 5 
(subscales Communication F=5.37, P=.02; Role Function F=5.40, P=.02) and difficulty (subscales 6 
Communication F=7.43, P=.006; Medical care F=4.04, P=.04; Role Function F=4.37, P=.04) of illness-7 
related stressful events than Control participants.  8 
Conclusions: The WebParC website for parents of children with JIA reduced illness-related parenting 9 
stress. This online intervention offers a feasible preventative approach for parents of children with 10 
JIA and potentially could be adapted and evaluated for parents of children with other chronic 11 
illnesses.  12 
Trial registration: International Standard Randomized Controlled Trial Number (ISRCTN): 3159730; 13 
http://www.isrctn.com/ISRCTN13159730.  14 








Parenting a child with juvenile idiopathic arthritis (JIA) presents many challenges, including dealing 2 
with their child's pain, distress and physical difficulties, managing medication, hospital visits (which 3 
may be a considerable distance from home), impact on schooling, financial issues such as time off 4 
work, and uncertainty about the future. In addition, in some healthcare systems there are 5 
substantial medication costs. Parents of children with JIA have concerns about their child’s 6 
treatment[1-3] and may experience anxiety and powerlessness concerning their child’s illness[4].  7 
Parenting stress is greater in parents of children with chronic illness compared to those with healthy 8 
children[5] and is associated with poorer psychological adjustment in both parents and children[5, 9 
6]. Given the interconnectedness between parent and child adjustment, early intervention to 10 
support parents may facilitate better adjustment for their children with JIA[7, 8]. Kazak’s Pediatric 11 
Psychosocial Preventative Health Model (PPPHM)[8] is a three-tier model for treating the families of 12 
children in paediatric health settings. The model offers a guide for matching psychosocial support to 13 
families’ level of need. It proposes that most families of children with chronic illnesses are likely to 14 
be distressed but resilient (Universal tier). A smaller group have risk factors for ongoing difficulties 15 
and require Targeted care. The smallest group, Clinical/Treatment, have a high level of risk factors 16 
for ongoing distress and require more intensive clinical services. Kazak stresses the need to adopt 17 
preventative approaches to support families in the Universal tier to build their resilience and prevent 18 
future problems[8].  19 
 20 
A potential preventative approach is to provide online interventions.  It is important that parents are 21 
able to access information from a trusted source[9], however health information on the internet is 22 
unregulated, often not validated through a systematic process[10], with variable quality[11, 12]. 23 
When developing this research, none of the websites providing information for children/young 24 
people with JIA and their parents had been evaluated in a randomised controlled trial (RCT) and 25 




We developed a website for parents of children with recently diagnosed JIA (‘WebParC’) [13] to 2 
complement usual clinical care with potential to help parents cope with the stress of their child 3 
having JIA. It is a specially designed web-based tool providing round-the-clock access to information 4 
and practical skills in dealing with specific problems (e.g. taking medication) and accessible as need 5 
arises. This paper reports the evaluation of WebParC.  6 
Aim  7 
To test that hypothesis that families provided with WebParC in addition to standard care would 8 
experience less illness-related parenting stress than those provided standard care alone.  9 
Methods 10 
Design 11 
Multi-centre RCT. 12 
Participating research sites  13 
Sixteen National Health Service tertiary paediatric rheumatology services in England (details 14 
available at http://www.isrctn.com/ISRCTN13159730).  15 
Ethical approval  16 
Approval obtained from Health Research Authority London Bridge Research Ethics Committee, 17 
reference 13/LO/0288.  18 
Research Participants:  19 
Parents attending rheumatology clinic appointments with their child, who met the following criteria: 20 
Inclusion Criteria:  21 
• Parent aged ≥18 years, with a child aged ≤12 years, newly diagnosed with JIA (within 22 
previous 6 months).  23 
o It was considered appropriate to focus the website on this age group as 24 
responsibility is taken mainly by parents in the child’s earlier years but tends to 25 
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move to the child as they get older so different strategies may be required for 1 
parents of adolescents.   2 
o JIA was diagnosed by a paediatric rheumatologist according to current International 3 
League of Associations for Rheumatology (ILAR) criteria[14]. ILAR criteria specify that 4 
JIA involves inflammation of the joints that begins before age 16 and persists for at 5 
least 6 weeks. ILAR categorise seven JIA subtypes, which differ in clinical course, and 6 
are based on the number of inflamed joints, laboratory tests and clinical features. 7 
The subtypes are: oligoarticular, polyarticular-RF negative; polyarticular-RF positive; 8 
systemic-onset; psoriatic; enthesitis-related and undifferentiated arthritis.  9 
o One or both parents could participate. Parents did not need to be living together, or 10 
with the child with JIA, to be eligible. 11 
• Internet access 12 
• Able to speak and read English.  13 
Exclusion Criteria:  14 
• Current severe mental illness such as identifiable psychosis in parents 15 
• Major problems with literacy making the questionnaire completion impossible 16 
• Likely to be distressed by the study as judged by their child’s rheumatologist. 17 
Procedures: 18 
Parents were invited to participate by their child’s rheumatologist when attending a clinic 19 
appointment with their child. Interested parents were given the opportunity to ask questions and 20 
were given the participant information sheet to read in clinic or to take home if they wished to have 21 
more time to consider participation. Those who wished to participate provided written consent to 22 
site research staff. If their child with JIA was aged 8-12 years, the child’s assent was obtained for 23 
their demographic and clinical data to be collected for the research. After providing consent, 24 
participants were given baseline questionnaires to complete in clinic or at home and return to the 25 
trial co-ordinating centre (freepost envelope provided). A link to an online version of the 26 
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questionnaire on Qualtrics software was also provided so parents could choose their preferred 1 
completion mode. Where both parents participated, they were given questionnaire packs with 2 
separate return envelopes and individual study IDs, which they entered into Qualtrics if they chose 3 
online completion. If the baseline questionnaire was not returned, a member of the site research 4 
team called participants. This was a change to the protocol made part-way through the trial to 5 
enhance questionnaire return rates. 6 
 7 
Randomisation: 8 
To minimise selection bias, participants were randomised by the trial co-ordinating centre after 9 
receipt of the completed baseline questionnaire. Randomisation was in a ratio of 1:1 to trial arms. 10 
Where both parents participated, they were randomised to the same trial arm (i.e. randomisation 11 
clustered by ‘household’). Blocked randomisation per site was performed using computer generated 12 
randomisation sequences which allowed varying randomisation block sizes. A combination of block 13 
sizes was used, varying between two, four and six, depending on site size; we used different sized 14 
blocks so that sites could not guess which group the last participant of a block would be randomised 15 
to. Allocation was concealed from clinical teams to avoid biasing clinical care, however, after 16 
allocation, it was not possible to blind the trial co-ordinator as the follow-up questionnaires 17 
contained additional questions about the website for intervention arm participants.  Other members 18 
of the investigating team were blind to trial arm allocation. Participants were requested not to 19 
inform their child’s clinicians of their trial arm allocation. 20 
Trial arms: 21 
Control arm: Children of control arm participants continued to receive standard clinical care as 22 
provided by the study site.  23 
Intervention arm: In addition to standard care, those allocated to the intervention arm were given 24 
free unlimited password-protected access to the website.  25 
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Website design 1 
The “JIA website for Parents” site was designed following [15]: 2 
a) a review of the literature on parents’ experiences of having a child with JIA 3 
b) a review of websites was conducted to find those that: (i) included information about JIA for 4 
parents, (ii) provided specific skills training for parents to manage their child’s JIA and (iii) 5 
contained information in English. Although many sites were found providing information 6 
about JIA, at the time of review, five main websites [16-20], which contained significant 7 
information for parents were reviewed in detail but none contained any skills training to 8 
assist parents. 9 
c) a focus group with six parents to ask their views on what should be included in the website 10 
d) two focus groups with a total of 12 healthcare professionals (HCPs) – six rheumatologists, 11 
five rheumatology nurse specialists, one clinical psychologist - to ask their views on what 12 
should be included in the website 13 
Website content was written by health professionals supported by a research assistant. The health 14 
professionals included: 13 rheumatologists, four rheumatology nurse specialists, two clinical 15 
psychologists, an occupational therapist, an ophthalmologist, two physiotherapists, a podiatrist and 16 
a social worker. A website consultant designed the site for layout, usability, acceptability, and 17 
interactive features.  18 
The resulting prototype website was tested by seven parents and eight health professionals (four 19 
rheumatologists, two rheumatology nurse specialists, one physiotherapist, one clinical psychologist), 20 
to evaluate usability, navigation, structure, layout and content. Small changes were made to the 21 
website after this assessment. These included: condensing some of the text; improving some text 22 
formatting with use of bullet points; some corrections to navigation links; re-naming some tabs with 23 
more user-friendly terms.   24 
Over the course of the website development but prior to trial commencement, the website was 25 
reviewed and updated to ensure user interfaces and content were current. Website content did not 26 
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change thereafter during the trial period. The website is device adaptive, so suitable for use on 1 
computer, tablet and smartphone.  2 
The website has two main components:  3 
1. information about JIA and its treatment. This comprises sections about: cause; diagnosis; JIA 4 
types and symptoms; how JIA changes with time; possible complications; the rheumatology 5 
team; everyday life, available treatments. 6 
It also includes videos of health professionals explaining JIA and its treatment plus video 7 
testimonials from parents about living with and caring for JIA as a family. 8 
2. a JIA toolkit, based on cognitive-behavioural therapy which includes: psycho-education about 9 
thoughts, feelings, and behaviour following a diagnosis; cognitive re-structuring techniques to 10 
challenge unhelpful thinking to promote coping with JIA; problem-solving skills to promote 11 
coping with adherence issues and stressful events; strategies to promote effective 12 
communication with family members and the health care team; and pain management 13 
techniques including cognitive re-structuring, relaxation, distraction, and pacing.  14 
The toolkit includes a number of downloadable resources: problem-solving sheet; thought diary; 15 
breaking negative thought cycle sheet; reward chart; procedure contract template and 16 
certificate; visual timetable; audio relaxation sessions for children and adults. 17 
Trial Measures (See Table 1). 18 
Parents provided demographic data including age, gender, educational level and relationship status.  19 
The primary outcome was parenting stress at 4-months post randomisation, measured with the 20 
Pediatric Inventory for Parents (PIP)[21], which is a validated measure to assess difficult events that 21 
parents may face. Respondents answer two questions for each event - how often it occurred in the 22 
past 7 days and how difficult it was for them.  The 4-month time-span was chosen to give parents 23 
sufficient time to make use of the website and to evaluate its effect in the short term. Follow-up 24 
times were also selected to fit around clinic visits.  25 
Secondary outcomes were: 26 
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• Parenting stress at 12 months post randomisation using the PIP[21]. This time-span was 1 
chosen to evaluate the medium-term effects of using the website.  2 
• Parent mood, assessed with the Hospital Anxiety and Depression Scale (HADS)[22].  3 
• Parent confidence in managing their child’s arthritis, assessed with the Parent’s Arthritis 4 
Self-efficacy Scale (PASE)[23].  5 
• Parent effectiveness in managing their child’s healthcare, assessed using the Effective 6 
Consumer Scale Adapted (ECS17-A)[24]. The original scale developed for adults with 7 
musculoskeletal disease was adapted to refer to how parents manage their child’s disease.  8 
• Parent satisfaction with healthcare, assessed with the Client Satisfaction Questionnaire 9 
(CSQ)[25].  10 
• A proxy measure of the child’s HRQoL was assessed with the Child Health Questionnaire 50-11 
item parent version (CHQ-PF50)[26].  12 
Process measures on website usage and parent coping and beliefs about their child’s illness (Brief 13 
COPE[27] and Brief Illness Perception Questionnaire[28] respectively) were collected but will be 14 
reported separately from the current paper, which focuses on the trial outcomes.    15 
 16 
Child data: Information about participants’ children with JIA (gender; age; JIA subtype; date of 17 
diagnosis; core outcome variables (number of inflamed and limited joints, erythrocyte 18 
sedimentation rate, Child Health Assessment Questionnaire, parent global rating, physician global 19 
rating)[29]; medication; and any related comorbidities were gathered by the clinical sites and sent 20 
securely to the trial co-ordinating centre. 21 
Follow up: 22 
At 4 and 12-months post-randomisation, the trial centre sent follow-up questionnaires both 23 
electronically and in hardcopy for participants to choose preferred completion method. Where both 24 
parents participated, they were posted the follow-up questionnaire packs individually and sent the 25 
link to the online questionnaire to their individual email addresses. Up to two telephone and/or text 26 
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reminders were sent if questionnaires were not returned within 2 weeks. Follow-up clinical data for 1 
the child (core outcome variables, medication and comorbidities) were obtained from trial sites’ 2 
clinic notes closest to the follow-up timepoints. 3 
Participants were sent a £5 gift voucher on return of each completed study questionnaire   A 4 
protocol change was made part-way through the trial to enhance questionnaire return rates but was 5 
paid retrospectively to all participants.   6 
 7 
   Table 1. Trial measures 8 
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 1 
Statistical Considerations 2 
Sample Size 3 
Both parents were invited to participate, therefore sample size calculation allowed for ‘clustering’ by 4 
household. The power calculation was based on the PIP primary outcome measure, assessed at 4 5 
15 
 
months post-randomisation. Standard deviations on the PIP frequency (PIP-F) and difficulty (PIP-D) 1 
scales were expected to be 25 [21]. Therefore 85 households per trial arm was considered adequate 2 
to detect a mean difference of 10 points with 80% power and 5% significance level, representing a 3 
medium effect size. This allowed for clustering by household, assuming an intra-cluster correlation 4 
of 0.5. Allowing for a 15% drop out, 100 households per trial arm (200 total) were needed. 5 
 6 
Statistical analysis 7 
Data were collected and stored in a secure manner and within Data Protection and GDPR guidelines. 8 
Analysis was conducted in IBM SPSS statistical software version 25.  9 
Missing value analysis, examined item-level missing data and used scale authors’ rules for dealing 10 
with missing data, where provided. If rules were not available, mean imputation within a scale was 11 
used when ≥50% of scale items were available. Little’s missing completely at random test was 12 
conducted to indicate the appropriateness of further imputations. If levels of missing data on any 13 
scale or item were >10%, multiple imputation was conducted (m=10). Data from all time points 14 
(baseline, 4-months and 12-months) were used to predict missing data, but the three time-points 15 
were imputed separately and only for participants who provided data at that time-point. Resultant 16 
databases were analysed separately, then Rubin’s rules[30, 31] were utilised to combine the results 17 
from the 10 datasets. Responders (those who completed at least one follow-up) were compared 18 
with non-responders on baseline characteristics using logistic regressions.  19 
 20 
Analyses were on an intention-to-treat basis. Outcomes were compared using multi-level modelling 21 
with a random effect of household, and adjusting for the variable at baseline and any parent and 22 
child demographic characteristics that differed between trial arms. We explored the main effects of 23 
time, trial arm and their interaction, by entering trial arm, time, and the interaction between trial 24 
arm and time as fixed effects, using restricted estimate maximum likelihood method. Significant 25 
interaction terms were interpreted as indicating differential treatment effectiveness and explored 26 
16 
 
with post hoc tests. Hedge’s g was calculated for effect sizes of differences between trial arms at 1 
each follow-up. 2 
 3 
Results 4 
Between February 2016 and October 2018, 717 parents were assessed for eligibility and 326 5 
consented to take part. Baseline questionnaires were returned by parents of 207 children 6 
(“households”). Four protocol violations were identified (diagnosis not JIA (n=2); >6 months since 7 
diagnosis (n=1); consent form not received (n=1)), leaving a final sample of 203 households (220 8 
parents), 100 households (106 parents) randomised to the intervention arm and 103 households 9 
(114 parents) to the control arm (Figure 1). Follow-up questionnaires were completed by 133 10 
(65.5%) households (141 parents) at 4 months and 124 (61.1%) households (128 parents) at 12 11 
months. Attrition did not differ significantly between Intervention and Controls at 4 months (χ2 = 12 
2.79, df1, p=0.10) or 12 months (χ2 = 0.54, df1, P=.47). Responders (completed one or both follow 13 
ups) differed from non-responders (completed neither follow up) on two baseline variables: mothers 14 
(146/183=79.8%) responded proportionally more than fathers (20/37=54.1%), (B=1.210, SE=0.378, 15 
P=.001, OR=3.354 (1.600-7.033 95%CI); and responders scored higher on the baseline ECS17-A Use 16 
of Health Information subscale (mean=77.4, SE=1.26) than non-responders (mean=71.0, SE=2.77), 17 
(B=0.020, SE=0.009, P=.02, OR=1.021 (1.003-1.039 95% CI).  18 
Missing values 19 
At baseline, 50 (58.8%) variables and 194 (88.2%) of cases had complete data, relating to an overall 20 
missing data level of 5.7%, (Little’s MCAR: Chi-Square=7356.6, df=7726, P=.999). At 4-months follow-21 
up, 118 (83.7%) cases followed-up had complete data, but no variables were complete, relating to an 22 
overall missing data level of 9.4%, (Little's MCAR test: Chi-Square=454.2, DF=3333, Sig.=1.000). At 23 
12-months follow-up 106 (82.8%) cases had complete data, with 40 (87.0%) variables having 24 
complete data, relating to an overall missing data level of 12.4%, (Little's MCAR test: Chi-25 
Square=140.3, DF=2978, Sig.=1.000). 26 
17 
 
Baseline characteristics 1 
Baseline characteristics are shown in Table 2. In 17 (8.4%) cases, both parents took part. Most 2 
participants were mothers (n=183, 83.2%). Parents’ average age was 36.5 (SD 6.5) and 70 (31.8%) 3 
were educated to degree level or above. Participants’ children with JIA were predominantly female 4 
(n=136, 67.0%), with a mean age of 6.1 (SD 3.4) years. The most frequent JIA subtypes were 5 
oligoarticular (n=107, 52.7%) and polyarticular (n= 65, 32.0%). 6 
 7 
Unadjusted means (SE) for all questionnaires at each timepoint are in Supplementary Table 1. No 8 
difference between the trial arms was found on any clinical or self-report questionnaire at baseline, 9 
however education level was higher in the intervention arm (mean=3.65, SD=1.63; controls 10 
(mean=3.17, SD=1.52; F(1,218)=5.221, P=.02). This was controlled for in all analyses. 11 
 12 
Table 2. Participant characteristics at baseline 13 
  Intervention Control Total 
Parent details 
Households, n 100 103 203 
Participants, n 106 114 220 
Parents, n (%) 
   Mother 
   Father 
  
  91 (85.8) 
  15 (14.2) 
  
  92 (80.7) 
  22 (19.3) 
  
183 (83.2) 
  37 (16.8) 
Age in years, mean (S.D.)  35.8 (6.5) 37.2 (6.4) 36.5 (6.5) 
Education*, n (%) 
   ≤GCSE or equivalent 
   Advanced level or equivalent 
   HNC/HND 









  7   (6.1) 
30 (26.3 
  
 85 (38.7) 
51 (23.2) 
14   (6.4) 
70 (31.8) 
Relationship status, n (%) 
   Single/Divorced/Separated 












  Intervention Control Total 
Living with child with JIA, n (%) 104 (98.1) 111 (97.4) 215 (97.7) 
Average number of children per family, mean (SE) 2.11 (0.09) 2.03 (0.09) 2.07 (0.06) 
Child with JIA details 
N 100 103 203 












Age in years, mean (S.D.) 6.3 (3.2) 6.0 (3.7) 6.1 (3.4) 
JIA subtype, n (%) 
   Systemic 
   Oligoarticular 
   Polyarticular 
   Psoriatic 
   ERA 
   Undifferentiated 
 
4   (4.0) 
58 (58.0) 
28 (28.0) 
6   (6.0) 
3   (3.0) 
1   (1.0) 
 
4   (3.9) 
49 (47.6) 
37 (35.9) 
5   (4.9) 
4   (3.9) 
4   (3.9) 
 
8   (3.9) 
107 (52.7) 
65 (32.0) 
11   (5.4) 
7    (3.4) 
5    (2.5) 
Current disease severity, median (IQR) 
   Number of active joints (known for n = 189) 
   Number of limited joints (known for n = 189) 
   CHAQ (known for n = 128) 
   Parent global (known for n = 117) 
   Physician global (known for n = 113) 




0.8 (0.3 - 1.3) 
3.3 (0.7 – 5.4) 
3.0 (1.5 – 6.0) 




0.8 (0 - 1.4) 
2.8 (1.0 - 6.0) 
2.0 (0.9 – 5.0) 




0.8 (0.1 – 1.3) 
3.0 (0.9 – 5.7) 
2.5 (1.0 – 5.0) 
20.2 (7.0 – 37.0) 
Medication 
   Methotrexate 
   Biologic 
  
31 (31.0) 
   0 
  
39 (37.9) 
   2  (1.9) 
  
70 (34.5) 
   2 (1.0) 
*Advanced level: national exam taken at approximately age 18; GCSE: General Certificate of 1 
Secondary Education, national exam taken at approximately age 16; HNC: higher national certificate; 2 
HND: higher national diploma  3 




Baseline questionnaire data (See Supplementary Table 1) 1 
The PIP asks about childhood illness-related events and therefore there has no normative data from 2 
parents of healthy children. PIP baseline Frequency (mean 108.45, SE 2.14; mothers: 111.04, 2.31; 3 
fathers: 95.68, 5.22) and Difficulty scores (102.84, 2.10; mothers:  104.73, 2.28; fathers: 93.48, 5.06) 4 
were worse than those reported by a sample of UK and US parents of children with a history of heart 5 
disease [32] (PIP-F  80.3 for mothers (mean diff=30.736, SE=2.306, t=13.13, df=7353301; P<.001) and 6 
76.2 for fathers  (mean diff=19.483, SE=5.219, t=3.73, df=5175615; P<.001);  PIP-D 80.6 for mothers 7 
(mean diff=24.132, SE=2.284, t=10.57, df=1063948; P<.001) and 75.7 for fathers (mean diff=17.776, 8 
SE=5.058, t=3.51, df=1806544; P<.001) and  UK parents of adolescents with chronic pain (25) (PIP-F 9 
104.9 (mean diff=3.554, SE=2.140, t=1.66, df=6166319; P=.097) and PIP-D 98.0 (mean diff=4.839, 10 
SE=2.097, t=2.31, df=569347; P=.021).  11 
  12 
Mean (SE) baseline scores for HADS Anxiety and Depression (9.04 (0.34) and 5.49 (0.29) respectively) 13 
were significantly worse than published UK  normative data [33] (mean anxiety 6.14 (SD 3.76); 14 
depression 3.68 (SD 3.07)) (anxiety: mean diff=2.896, SE=0.341, t=8.49, df=62011; P<.001; 15 
depression: mean diff=1.806, SE=0.285, t=6.33, df=196469; P<.001). Participants scoring in the ‘mild’ 16 
(score 8-10), ‘moderate’ (11- 14) or ‘severe’ (15-21) ranges for anxiety were 48 (21.8%), 47 (21.4%) 17 
and 34 (15.5%) and for depression were 43 (19.5%), 24 (10.9%) and 3 (1.4%) respectively.  This 18 
compares with 19% of women and 12.5% of men scoring in the moderate/severe range for anxiety 19 
and 6.9% of both men and women for depression in a UK normative sample [34].   20 
 21 
Baseline PASE self-efficacy scores (mean, SE) were 4.44 (0.15) for Symptoms (mothers: 4.42, 0.16; 22 
fathers: 4.54, 0.39), and 5.80, 0.15 for Psychosocial (mothers:  5.78, 0.16; fathers: 5.92, 0.14). These 23 
are approximately at the scale mid-point and are worse than those reported in the original scale 24 
validation[23] by mothers (Symptoms: mean diff=-0.428, se=0.157, t=-2.73, df=8485; P=.006; 25 
Psychosocial: mean diff=-0.620, se=0.164, t=-3.77, df=3078; P<.001) but not fathers (Symptoms: 26 
20 
 
mean diff=0.681, se=0.385, t=1.77, df=12222; P=.08; Psychosocial: mean diff=-0.308, se=0.414, t=-1 
0.74, df=6936; P=.46)). 2 
 3 
Mean (SE) total score on the ECS-17A was 77.87 (0.97). This score reflects that on average parents 4 
felt they could ‘usually’ manage their child’s healthcare. Mean (SE) scores on the CSQ-8 of 28.4 5 
(0.24) reflect very high satisfaction with health services.  6 
 7 
The CHQ-PF50 health-related quality of life summary scores of participants’ children were mean 33.4 8 
(SE 0.95) for physical quality of life and 44.4 (SE 0.72) for psychosocial quality of life, which is poorer 9 
than scores reported for UK healthy controls [26] (55.4 (SD 4.2) (mean difference=-21.999, se=0.947, 10 
t=-23.23, df=34421, P<.001) and 51.6 (SD 7.1) (mean difference=-7.199, se=0.721, t=-9.98, df=27490, 11 
P<.001) respectively). 12 
 13 
Trial outcomes 14 
Tables 3 & 4 present adjusted means at each follow-up per group and multi-level modelling analyses 15 
estimates for the effect of trial arm, time and interaction on all outcomes, adjusted for baseline 16 
scores and education level, respectively. The use of random effects for parent clusters was not 17 
possible as the number of dyad clusters was too few and random effects analyses did not converge. 18 
Consequently, parents were treated as individual units.  Post-hoc comparisons of trial arm effects at 19 
4-months and 12-months are reported in Supplementary Table 2. The direction of effects, shown in 20 








Table 3. Follow-up Adjusted Means (adjusted for baseline scores and educational level) on each outcome for 1 
the control and intervention groups following MLM Analysis 2 
 Control Intervention 
 4 months 12 months 4 months 12 months 






























PIP Frequency              
Communication  19.01 17.86 20.16 19.47 18.27 20.68 17.45 16.16 18.74 17.36 16.05 18.67 
Medical care  18.29 16.95 19.63 18.48 17.04 19.91 16.80 15.30 18.31 16.63 15.07 18.20 
Emotional Distress  37.86 35.65 40.07 36.95 34.68 39.21 35.43 32.95 37.90 35.08 32.60 37.57 
Role Function  19.50 18.24 20.76 20.10 18.77 21.42 18.16 16.75 19.57 17.74 16.28 19.21 
Frequency Total 94.38 89.04 99.73 94.62 89.13 100.11 88.32 82.32 94.31 87.26 81.27 93.24 
PIP Difficulty              
Communication  17.64 16.45 18.82 18.13 16.87 19.39 15.82 14.52 17.12 15.57 14.24 16.90 
Medical care  16.88 15.53 18.23 16.57 15.21 17.93 14.89 13.37 16.41 14.49 12.98 16.00 
Emotional Distress  38.87 36.33 41.41 38.47 35.93 41.00 35.85 32.98 38.72 35.08 32.32 37.84 
Role Function  19.15 17.73 20.57 19.39 17.97 20.82 17.57 15.99 19.16 17.10 15.51 18.68 
Difficulty Total 92.63 86.86 98.40 92.35 86.77 97.93 84.09 77.60 90.58 81.82 75.76 87.87 
HADS             
Anxiety  8.33 7.57 9.09 7.86 7.01 8.71 7.61 6.75 8.46 7.95 7.02 8.87 
Depression  5.52 4.82 6.21 5.64 4.93 6.35 4.78 4.00 5.57 5.05 4.27 5.84 
PASE             
Symptoms 5.31 4.92 5.69 5.09 4.65 5.52 5.03 4.57 5.49 5.71 5.24 6.18 
Psychosocial 6.58 6.12 7.03 6.31 5.83 6.79 6.55 6.04 7.06 6.64 6.11 7.16 
ECS-17A             
Use Health Info 76.70 73.47 79.93 78.32 75.31 81.32 75.07 73.22 76.92 81.04 79.36 82.73 
Clarify Priorities 82.89 80.07 85.72 83.65 80.64 86.67 81.94 78.79 85.08 85.62 82.37 88.87 
Communicate with 
others 85.21 82.29 88.14 84.20 81.32 87.08 79.87 78.19 81.55 87.34 85.74 88.94 
Negotiate roles 75.45 72.12 78.79 76.03 72.63 79.42 74.59 70.85 78.32 79.79 76.10 83.49 
Decide and act 77.01 73.82 80.20 76.90 73.97 79.83 75.12 71.53 78.70 80.84 77.64 84.04 
ESC Total 79.15 76.66 81.64 79.45 76.90 82.01 76.67 73.88 79.46 82.51 79.73 85.29 
CSQ8 28.30 27.51 29.09 28.07 27.30 28.84 28.70 27.81 29.59 28.51 27.67 29.35 
CHQ-PF50             
Physical Functioning  74.49 69.83 79.15 76.80 71.94 81.66 80.35 75.10 85.61 83.02 77.73 88.30 
Role / Social Emotional / 
Behavioral  80.79 75.72 85.85 83.62 78.83 88.40 87.94 82.25 93.63 87.22 82.02 92.43 
Role / Social Physical  78.77 73.63 83.92 80.17 75.03 85.31 85.86 80.06 91.66 86.75 81.16 92.35 
Bodily Pain and 
Discomfort  58.85 54.06 63.63 62.40 57.02 67.77 66.55 61.16 71.94 67.27 61.40 73.14 
Behavior  67.15 63.86 70.43 67.19 63.87 70.51 66.61 62.90 70.32 69.66 66.05 73.27 
Mental Health  71.22 68.40 74.04 72.77 69.46 76.08 75.19 72.03 78.34 71.60 68.01 75.20 
Self Esteem  70.06 66.43 73.70 76.42 72.62 80.22 76.23 72.13 80.34 77.02 72.89 81.14 
General Health 
Perceptions  52.41 49.31 55.52 54.74 51.39 58.09 56.27 52.78 59.77 57.31 53.65 60.97 
22 
 
 Control Intervention 
 4 months 12 months 4 months 12 months 






























Emotional Impact on 
Parent  63.69 58.95 68.44 63.60 58.99 68.20 67.74 62.38 73.10 68.52 63.50 73.54 
Parental Impact 75.58 70.84 80.32 81.99 77.65 86.34 82.84 77.49 88.19 84.80 80.10 89.51 
Family Activities  71.69 67.88 75.51 73.47 69.29 77.65 77.01 72.72 81.30 79.09 74.52 83.65 
Family Cohesion  76.27 72.09 80.44 74.03 69.89 78.17 78.53 73.81 83.24 79.89 75.41 84.37 
Physical Summary 
Scores 39.62 37.14 42.09 41.56 38.90 44.22 43.06 40.32 45.80 44.51 41.63 47.40 
Psychosocial Summary 
Scores 45.78 44.00 47.56 48.06 46.15 49.96 48.79 46.78 50.79 48.68 46.61 50.75 
* Adj. Mean - Adjusted Mean for baseline scores and educational level 1 
 2 
 3 
Table 4. Multi-level modelling analyses of each outcome exploring time and trial arm main effects 4 
and their interaction. 5 
 Effect 
 Trial Arm Time Time * Trial Arm 
Variable DF2 F P DF2 F P DF2 F P 
PIP Frequency           
Communication  120627 5.37 .021 225948 0.01 .904 218596 0.32 .575 
Medical care  36383 2.87 .090 145323 0.04 .838 45835 0.01 .753 
Emotional Distress  69328 1.17 .280 115020 0.07 .794 129609 0.10 .748 
Role Function  27203 5.40 .020 89283 0.34 .557 67018 1.10 .295 
Frequency Total 7872787 3.14 .077 2123768 0.12 .734 3941957 0.09 .759 
PIP Difficulty           
Communication  2237 7.43 .006 6133 0.09 .760 5150 0.45 .501 
Medical care  2907 4.04 .044 1715 0.20 .658 6475 0.01 .937 
Emotional Distress  6128 3.10 .078 7769 0.22 .639 15313 0.03 .868 
Role Function  821 4.37 .037 1028 0.25 .621 1590 0.31 .577 
Difficulty Total 588193 6.30 .012 115056 0.37 .542 194822 0.16 .691 
HADS          
Anxiety  3123 0.02 .894 6920 0.56 .454 5892 1.72 .192 
Depression  11080 1.16 .281 4597 0.41 .523 12694 0.07 .799 
PASE          
Symptoms 10281 3.63 .057 961 4.80 .029 7284 4.90 .027 
Psychosocial 7031 0.84 .359 12798 0.07 .791 3629 0.59 .444 




 Trial Arm Time Time * Trial Arm 
Variable DF2 F P DF2 F P DF2 F P 
Use Health Info 4.68E+09 1.42 .233 7.90E+10 9.90 .002 4.56E+08 2.89 .089 
Clarify Priorities 1.95E+08 0.75 .386 8.41E+12 3.56 .059 3.55E+07 1.22 .269 
Communicate with 
others 2.03E+09 2.08 .149 2.07E+11 14.66 <.001 2.07E+08 10.33 .001 
Negotiate roles 1.40E+08 2.16 .142 1.33E+13 6.21 .013 5.77E+06 2.68 .101 
Decide and act 7.55E+06 3.17 .075 1.79E+08 8.63 .003 1.22E+07 4.91 .027 
ESC Total 2.29E+07 2.51 .113 7.75E+07 14.04 <.001 4.36E+06 6.90 .009 
CSQ8 16736 0.57 .449 30483 0.16 .685 14841 0.00 .952 
CHQ-PF50          
Physical Functioning  546164 2.88 .090 403462 0.77 .380 533107 0.01 .932 
Role / Social / 
Emotional / Behavioral  360571 1.00 .318 454651 0.05 .821 577910 0.69 .408 
Role / Social Physical  273546 2.89 .089 359145 0.07 .794 66209 0.01 .913 
Bodily Pain and 
Discomfort  1039728 1.44 .230 579724 0.06 .805 777799 0.50 .478 
Behavior  37269 0.97 .325 48284 1.98 .160 28885 1.05 .306 
Mental Health  96801 0.22 .641 264228 2.83 .093 83261 3.15 .076 
Self Esteem  22019 0.04 .836 92848 0.10 .754 71775 2.73 .099 
General Health 
Perceptions  198499 1.03 .310 353837 0.28 .592 174477 0.24 .624 
Emotional Impact on 
Parent  199245 2.00 .157 394803 0.07 .789 434994 0.05 .824 
Parental Impact 650668 0.74 .391 434479 0.46 .499 237236 1.27 .259 
Family Activities  186376 3.13 .077 396224 0.77 .381 493035 0.01 .926 
Family Cohesion  225860 3.53 .060 222878 0.21 .645 321685 0.81 .369 
Physical Summary 
Scores 8378 2.13 .144 27479 0.93 .334 8741 0.06 .812 
Psychosocial Summary 
Scores 6310 0.19 .664 5005 0.01 .927 1647 2.31 .129 
 1 
 2 
Parenting stress 3 
A significant effect of trial-arm over the two follow-up periods was found on the PIP-F 4 
Communication and Role Function subscales, and on the PIP-D Communication, Medical care and 5 
Role function subscales and the PIP-D total score. In each instance, participants in the Intervention 6 
arm reported less frequency and difficulty of illness-related stressful events than participants in the 7 
Control arm. Post-hoc comparisons (Supplementary Table 2) found that these effects mostly reached 8 




Anxiety and Depression 2 
We did not find a significant effect of the intervention on mean anxiety or depression scores.   3 
 4 
Parental Arthritis Self-efficacy  5 
No significant effect of trial arm was found on the PASE. However, there was a significant time effect 6 
on PASE Symptoms, where the whole sample improved over the 12-month period.  In addition, there 7 
was a significant interaction effect on PASE Symptoms; participants in the Intervention arm reported 8 
greater improvement in their self-efficacy from 4 to 12-months than Controls.  9 
 10 
Effective Consumer Scale 11 
We did not find an overall effect of trial arm on parents’ perceived effectiveness in managing their 12 
child’s healthcare assessed with the ECS17-A. We found significant interaction effects on the 13 
Communicating with others and Deciding and taking action subscales. For Communicating with 14 
others there was a significant trial arm effect at 4-months favouring the control arm but the control 15 
arm did not change between 4 and 12 months while the intervention arm improved significantly. For 16 
Deciding and taking action, there was no effect of trial arm at 4 or 12 months, the control arm did 17 
not change between 4 and 12 months but the intervention arm improved significantly.   We found a 18 
main effect of time on the Use of Health Information and Negotiating roles and taking control 19 
subscales with an improvement in the overall sample on both subscales. There was no effect on the 20 
Clarifying personal priorities subscale.  21 
 22 
Satisfaction with Healthcare 23 
Satisfaction with health care services was very high at baseline and remained so at follow-ups with 24 




Child’s health-related quality of life 1 
There was no significant overall effect of trial arm on parents’ assessment of their child’s health-2 
related quality of life on the CHQ-PF50.  3 
 4 
Discussion 5 
This RCT evaluated the “WebParC” website for parents of children with JIA. To our knowledge, this is 6 
the first website for parents of children with JIA that has undergone evaluation in a randomised 7 
controlled trial. The website was found to be successful in reducing child illness-related parenting 8 
stress and also promoted a greater improvement in parents’ self-efficacy in managing children’s 9 
symptoms.    10 
 11 
Although the direction of effects mostly favoured the intervention, post hoc comparisons indicate 12 
they did not reach statistical significance until 12 months. This suggests that it is in the longer-term 13 
that the knowledge and skills parents gain from the website significantly reduce their stress and 14 
improve symptom self-efficacy.  15 
  16 
Satisfaction with healthcare was very high among parents throughout this trial, indicating that even 17 
in the context of excellent clinical care, parents experience stress related to their child’s illness.  This 18 
trial has shown that a web-based intervention, accessible when needed outside the clinical setting, 19 
can help parents to manage the stresses of having a child with JIA and could be offered to parents as 20 
an adjunct to the care given to their child.   The effect sizes achieved ranged from small to medium, 21 
which is acceptable for a very ‘light touch’ intervention that demands little additional resources. 22 
 23 
Scores on the Communicating with others subscale of the ECS-17A were high at all timepoints, 24 
reflecting a good degree of confidence in communicating with the healthcare team across the trial 25 
period. However, the intervention arm scores deteriorated at 4 months before improving again at 12 26 
26 
 
months. The drop at 4 months may indicate that access to the website meant that parents were less 1 
likely to engage with healthcare professionals in the early stage but had more interaction and built 2 
up confidence in the longer term. 3 
 4 
The parent outcomes improved by the website were those relating to the stress of communication, 5 
managing medical aspects of their child’s care including symptoms, and carrying out everyday family 6 
and social roles. It is important that the website, which covers information about JIA and its 7 
treatment, including potentially distressing issues such as medication side effects, did not have any 8 
negative effect on parents’ psychological wellbeing. Two of the three main ‘tasks’ in living with a 9 
chronic illness proposed by Corbin and Strauss (1988)[35]: medical management and role 10 
management, were improved by WebParC. The third task, managing emotions, was unchanged.  11 
 12 
We were unable to identify evaluations of other interventions specifically for parents of children 13 
with JIA. A review of interventions for parenting stress in families with paediatric conditions[36] did 14 
not include any online interventions. A Cochrane review of 47 psychological interventions for 15 
parents of children with  chronic illnesses [37], included six that were delivered at least partly online. 16 
Of these, only two small trials (n<40) assessed parental mental health; therapist-supported online 17 
family problem-solving [38] for traumatic brain injury was found to be beneficial but part-online CBT 18 
[39] did not have an effect on the mental health of parents who had a child with cancer. The primary 19 
target of WebParC was parenting stress rather than mental health; using online approaches to 20 
support the mental health of parents of children with JIA may require a greater focus on parents’ 21 
psychological well-being than we were able to achieve in WebParC. 22 
 23 
Limitations of the study, in common with interventions of this type, include that it was not possible 24 
to blind participants to trial arm allocation. Although requested not to inform their child’s clinicians 25 
of their allocation, it is not possible to know if all participants followed this request.  We made every 26 
27 
 
effort to ensure that where both parents participated, questionnaires were given to the individual 1 
parent for completion. Although we consider it unlikely, it is nonetheless possible that one parent 2 
completed both copies.  However, the number of questionnaires received from both parents is 3 
small.   A proportion of parents who consented to participate in the trial did not return the baseline 4 
questionnaire and were therefore not randomised. The follow-up response rates were also lower 5 
than expected. Parents may have forgotten or not prioritised questionnaire completion; when 6 
reminders and a small incentive were introduced mid-trial, rates of baseline and follow-up 7 
questionnaire return improved.  Another possibility is that although parents consented to the trial 8 
when they were in clinic, taking part in research about their own well-being, rather than their child’s, 9 
was not a priority for them.  Parents who did not return the baseline questionnaire may also have 10 
been reluctant to answer detailed questions about their own and their child’s wellbeing. These 11 
issues will need to be considered in future studies of this type.  12 
 13 
In common with other research[40], fathers were less likely to participate, which occurred in this 14 
trial because they were less likely than mothers to attend the clinic.  It was not possible to establish 15 
whether non-participating fathers may have been given access to the website by participating 16 
partners.  The small number of cases where both parents participated meant we were unable to 17 
cluster by household in our analyses.  18 
 19 
To minimise participant burden, outcomes were assessed at only two follow-up times, 4-months and 20 
12-months after randomisation. These were chosen for pragmatic reasons and to allow parents time 21 
to use the website before assessing its impact in the short and medium-to-longer term.  We 22 
acknowledge that we will not have been able to capture all potential stressors that may have 23 
occurred and coping strategies used between the baseline and follow-up periods but more frequent 24 




Primary analyses with the PIP scales utilised a P<.05 value for significance as per the protocol. For 1 
secondary analyses on additional scales we did not adjust the p-value of <0.05 to allow for multiple 2 
testing so caution while interpreting should be taken. It is notable however, that the pattern of our 3 
findings, even where not statistically significant, were mostly in the direction favouring the 4 
Intervention arm therefore it is unlikely that our significant findings reflect type I error. 5 
 6 
In conclusion, the study reported in this paper has demonstrated that online interventions for 7 
parents of children with Juvenile arthritis which combine information and skills training can result in 8 
significant benefits for parents. The benefits of reduced illness-related parenting stress and 9 
improvements in confidence, self-efficacy, regarding parenting skills are important for a group not 10 
often seen as a high priority in healthcare.  Future studies should attempt to devise techniques that 11 
reduce the loss to follow up that was higher than projected in this study.  In general, online 12 
interventions for parents of children with a chronic illness should be made a priority as they are easy 13 
to access at any time, replicable and can offer a preventative approach to a large number of parents.  14 
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